Patents by Inventor Matthieu Germain
Matthieu Germain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11471410Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm.Type: GrantFiled: August 26, 2019Date of Patent: October 18, 2022Assignee: CURADIGM SASInventors: Matthieu Germain, Marie-Edith Meyre, Agnès Pottier, Laurent Levy
-
Patent number: 11357724Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest to a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered to said subject between more than 5 minutes and about 72 hours from each other.Type: GrantFiled: August 29, 2019Date of Patent: June 14, 2022Assignee: CURADIGM SASInventors: Agnès Pottier, Laurent Levy, Marie-Edith Meyre, Audrey Darmon, Matthieu Germain
-
Patent number: 11304902Abstract: The present disclosure generally relates to the field of medicine. The present invention more specifically relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle comprising, or consisting in, at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of said nanoparticle being of at least 4 nm and less than 100 nm, and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the combination of the at least one biocompatible nanoparticle and of the at least one compound of interest potentiates the at least one compound of interest's bioavailability.Type: GrantFiled: November 24, 2015Date of Patent: April 19, 2022Assignee: CURADIGM SASInventors: Agnes Pottier, Matthieu Germain, Laurence Poul, Marion Paolini, Marie-Edith Meyre
-
Patent number: 11191846Abstract: The invention pertains to a therapeutic, prophylactic or diagnostic method comprising, administering a pharmaceutical compound followed by administering a biocompatible nanoparticle comprising an oligomer of albumin, wherein the longest or largest dimension of the nanoparticle is between about 4 nm and about 500 nm. In preferred embodiments, administering the biocompatible nanoparticles is performed between more than 5 minutes and about 72 hours after administering the pharmaceutical compound. In particular embodiments, the pharmaceutical compound is a pharmaceutical antibody, such as a monoclonal antibody, a drug conjugated antibody, an engineered antibody and a multispecific antibody.Type: GrantFiled: August 1, 2018Date of Patent: December 7, 2021Assignee: CURADIGM SASInventors: Marie-Edith Meyre, Agnes Pottier, Matthieu Germain, Celine Berjaud, Audrey Darmon
-
Patent number: 10765632Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and (ii) at least one carrier comprising at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the combination of the at least one biocompatible nanoparticle and of the at least one carrier comprising the pharmaceutical compound(s) potentiates the compound(s) of interest effectiveness in therapy, prophylaxis or diagnosis. The invention also relates to such a composition for use for administering the pharmaceutical compound(s) in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one carrier comprising the at least one pharmaceutical compound are to be administered separately in a subject in need of said pharmaceutical compound, typically between more than 5 minutes and about 72 hours one from each other.Type: GrantFiled: November 24, 2015Date of Patent: September 8, 2020Assignee: CURADIGM SASInventors: Matthieu Germain, Marie-Edith Meyre, Agnes Pottier, Laurent Levy
-
Patent number: 10588987Abstract: The present invention relates to compositions and methods for use in medical diagnosis and patient monitoring. It more particularly relates to a biocompatible gel comprising nanoparticles and/or nanoparticle aggregates, wherein: i) the nanoparticles and/or nanoparticles of said aggregate comprise an inorganic material comprising at least one metal element having an atomic number Z of at least 25, each of said nanoparticles and nanoparticle aggregates being covered with a biocompatible coating; ii) the nanoparticles' and/or nanoparticle aggregates' concentration is of about or less than 0.5% (w/w); and iii) the apparent viscosity at 2 s?1 of the gel comprising the nanoparticles and/or nanoparticle aggregates is between about 0.1 Pa·s and about 1000 Pa·s when measured between 20° C. and 37° C. The composition of the invention typically allows the delineation and visualization of at least 40% of the target biological tissue when said tissue is observed using an X-ray imaging equipment.Type: GrantFiled: June 19, 2014Date of Patent: March 17, 2020Assignee: NANOBIOTIXInventors: Laurence Poul, Laurent Levy, Celine Berjaud, Matthieu Germain, Agnes Pottier
-
Publication number: 20200009050Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest to a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered to said subject between more than 5 minutes and about 72 hours from each other.Type: ApplicationFiled: August 29, 2019Publication date: January 9, 2020Inventors: AGNÈS POTTIER, LAURENT LEVY, MARIE-EDITH MEYRE, AUDREY DARMON, MATTHIEU GERMAIN
-
Publication number: 20190374465Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm.Type: ApplicationFiled: August 26, 2019Publication date: December 12, 2019Inventors: MATTHIEU GERMAIN, MARIE-EDITH MEYRE, AGNÈS POTTIER, LAURENT LEVY
-
Publication number: 20190314530Abstract: The present invention relates to compositions and methods for use in medical diagnosis and patient monitoring, typically in the context of therapy, in particular in the context of oncology, to optimize tumor bed local irradiation. It more particularly relates to a biocompatible gel comprising nanoparticle and/or nanoparticle aggregates, wherein: i) the density of each nanoparticle and of each nanoparticle aggregate is at least 7 g/cm3, the nanoparticle or nanoparticles of the aggregate comprising an inorganic material comprising at least one metal element having an atomic number Z of at least 25, more preferably of at least 40, each of said nanoparticle and nanoparticle aggregate being covered with a biocompatible coating; ii) the nanoparticles' and/or nanoparticle aggregates' concentration is of at least about 1% (w/w); and iii) the apparent viscosity at 2 s?1 of the gel comprising nanoparticles and/or nanoparticle aggregates is between about 0.1 Pa·s and about 1000 Pa·s when measured between 20° C.Type: ApplicationFiled: May 28, 2019Publication date: October 17, 2019Inventors: LAURENCE POUL, LAURENT LEVY, CELINE BERJAUD, MATTHIEU GERMAIN, AGNÉS POTTIER
-
Patent number: 10413509Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) a biocompatible nanoparticle and of (ii) a pharmaceutical compound of interest, to be administered to a subject in need of such a compound of interest, wherein the nanoparticle potentiates the compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm, and its absolute surface charge value is of at least 10 mV (|10 mV|). The invention also relates to such a composition for use for administering the compound of interest to a subject in need thereof, wherein the nanoparticle and the compound of interest are to be administered to said subject between more than 5 minutes and about 72 hours from each other.Type: GrantFiled: May 30, 2014Date of Patent: September 17, 2019Assignee: NANOBIOTIXInventors: Agnés Pottier, Laurent Levy, Marie-Edith Meyre, Audrey Darmon, Matthieu Germain
-
Patent number: 10391058Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm.Type: GrantFiled: November 24, 2015Date of Patent: August 27, 2019Assignee: NANOBIOTIXInventors: Matthieu Germain, Marie-Edith Meyre, Agnes Pottier, Laurent Levy
-
Patent number: 10265406Abstract: The present application relates to a pharmaceutical composition comprising biocompatible nanoparticles or nanoparticles aggregates which allows the appropriate delivery of said biocompatible nanoparticles or nanoparticles aggregates to a target site in a subject in need thereof. The composition indeed allows an accumulation of the biocompatible nanoparticles or nanoparticles aggregates it comprises into the targeted tissue of the subject of at least 4 milligram (mg) nanoparticles or nanoparticles aggregates per gram (g) of targeted tissue when at least 0.1 g of the pharmaceutical composition per kilogram (kg) of body weight is injected intravenously (IV) or intraarterially (IA) into said subject.Type: GrantFiled: December 19, 2014Date of Patent: April 23, 2019Assignee: NANOBIOTIXInventors: Agnes Pottier, Laurent Levy, Matthieu Germain
-
Publication number: 20180339062Abstract: The invention pertains to a therapeutic, prophylactic or diagnostic method comprising, administering a pharmaceutical compound followed by administering a biocompatible nanoparticle comprising an oligomer of albumin, wherein the longest or largest dimension of the nanoparticle is between about 4 nm and about 500 nm. In preferred embodiments, administering the biocompatible nanoparticles is performed between more than 5 minutes and about 72 hours after administering the pharmaceutical compound. In particular embodiments, the pharmaceutical compound is a pharmaceutical antibody, such as a monoclonal antibody, a drug conjugated antibody, an engineered antibody and a multispecific antibody.Type: ApplicationFiled: August 1, 2018Publication date: November 29, 2018Inventors: MARIE-EDITH MEYRE, AGNES POTTIER, MATTHIEU GERMAIN, CELINE BERJAUD, AUDREY DARMON
-
Patent number: 10064962Abstract: The invention pertains to a method of monitoring the membrane permeabilization of a liposome and the incidental release of a compound of interest. The method utilizes liposomes comprising a thermosensitive lipidic membrane encapsulating the product of interest and superparamagnetic nanoparticles having the electrostatic surface charge below ?20 mV or above +20 mV when measured in an aqueous medium at physiological pH. In one embodiment, the method comprises the steps of: a) measuring relaxation time (T2*); b) heating the liposome at Tm or above Tm; c) measuring T2* after step b); d) obtaining the transverse relaxivity (r2*) values from the T2* values obtained from step a) and step c); and e) determining the ratio of r2* before and after the heating step b). A ratio above 1.5 indicates the liposome membrane permeabilization and the incidental release of the product of interest.Type: GrantFiled: October 19, 2015Date of Patent: September 4, 2018Assignees: NANOBIOTIX, UNIVERSITE DE BORDEAUX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Agnés Pottier, Laurent Levy, Marie-Edith Meyre, Matthieu Germain, Cyril Lorenzato, Chrit Moonen, Pierre Smirnov
-
Patent number: 9956175Abstract: The invention pertains to thermosensitive liposomes encapsulating nanoparticles. In certain embodiments, the thermosensitive liposomes of the invention disrupt when heated at gel-to-liquid crystalline phase transition temperature (Tm) or above Tm, wherein the liposome comprises a thermosensitive lipidic membrane encapsulating nanoparticles. The nanoparticles used in the invention comprise an inorganic core the largest dimension of which is less than about 100 nm that is fully coated with an agent responsible for the presence of an electrostatic charge below ?20 mV or above +20 mV at the surface of the nanoparticle, the electrostatic charge being determined by zeta potential measurements in an aqueous medium between pH 6 and 8, for a concentration of nanoparticles in suspension in the aqueous medium varying between 0.2 and 8 g/L. The invention also relates to pharmaceutical and diagnostic compositions comprising the thermosensitive liposomes as well as to their uses.Type: GrantFiled: January 31, 2012Date of Patent: May 1, 2018Assignee: NANOBIOTIXInventors: Agnès Pottier, Laurent Levy, Marie-Edith Meyre, Matthieu Germain
-
Publication number: 20170258717Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm.Type: ApplicationFiled: November 24, 2015Publication date: September 14, 2017Inventors: Matthieu GERMAIN, Marie-Edith MEYRE, Agnès POTTIER, Laurent LEVY
-
Publication number: 20170258720Abstract: The present disclosure generally relates to the field of medicine. The present invention more specifically relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle comprising, or consisting in, at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of said nanoparticle being of at least 4 nm and less than 100 nm, and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the combination of the at least one biocompatible nanoparticle and of the at least one compound of interest potentiates the at least one compound of interest's bioavailability.Type: ApplicationFiled: November 24, 2015Publication date: September 14, 2017Inventors: AGNES POTTIER, MATTHIEU GERMAIN, LAURENCE POUL, MARION PAOLINI, MARIE-EDITH MEYRE
-
Publication number: 20170258937Abstract: The invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle, said biocompatible nanoparticle comprising at least one oligomer of albumin (n?2) or consisting in an oligomer of albumin, and of (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least one nanoparticle potentiates the at least one compound of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm. The invention also relates to such a composition for use for administering the at least one compound of interest in a subject in need thereof, wherein the at least one biocompatible nanoparticle and the at least one compound of interest are to be administered in said subject sequentially, typically between more than 5 minutes and about 72 hours one from each other.Type: ApplicationFiled: November 24, 2015Publication date: September 14, 2017Inventors: Marie-Edith MEYRE, Agnès POTTIER, Matthieu GERMAIN, Céline BERJAUD, Audrey DARMON
-
Publication number: 20170258721Abstract: The present invention relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle and (ii) at least one carrier comprising at least one pharmaceutical compound, to be administered to a subject in need of such a pharmaceutical compound, wherein the combination of the at least one biocompatible nanoparticle and of the at least one carrier comprising the pharmaceutical compound(s) potentiates the compound(s) of interest efficiency. The longest dimension of the biocompatible nanoparticle is typically between about 4 and about 500 nm and its absolute surface charge value is of at least 10 mV (|10 mV|). The carrier is in addition devoid of any surface sterically stabilizing agent.Type: ApplicationFiled: November 24, 2015Publication date: September 14, 2017Inventors: MATTHIEU GERMAIN, MARIE-EDITH MEYRE, AGNES POTTIER, LAURENT LEVY
-
Publication number: 20160310614Abstract: The present application relates to a pharmaceutical composition comprising biocompatible nanoparticles or nanoparticle aggregates which allows the appropriate delivery of said biocompatible nanoparticles or nanoparticle aggregates to a target site in a subject in need thereof. The composition indeed allows an accumulation of the biocompatible nanoparticles or nanoparticle aggregates it comprises into the targeted tissue of the subject of at least 4 milligram (mg) nanoparticles or nanoparticle aggregates per gram (g) of targeted tissue when at least 0.1 g of the pharmaceutical composition per kilogram (kg) of body weight is injected intravenously (IV) or intraarterially (IA) into said subject.Type: ApplicationFiled: December 19, 2014Publication date: October 27, 2016Inventors: AGNES POTTIER, LAURENT LEVY, MATTHIEU GERMAIN